Hematocrit Values in the CAPD/CCPD Population
A survey of the National CAPD Registry population was conducted to assess the distribution of hematocrit in a large group of CAPD/CCPD patients to characterize the anemia of the population, and identify factors which relate to variation in hematocrit. A random sample of 812 patients was selected from the Registry population. Information was provided on 608 patients. Population characteristics were similar to the Registry population as a whole. Mean hematocrit was 29.4% and median hematocrit was 29%. Recent peritonitis, folate therapy, androgen therapy, and iron therapy had no obvious influences on hematocrit distributions. Significantly higher hematocrits were seen in males, whites, and patients with polycystic kidney disease. Significantly lower hematocrits were seen in surgically anephric patients and in patients who had received transfusions 60 days before the survey. Eighty-nine percent of patients had not received a transfusion 60 days prior to the survey. Some patients, especially those with hematocrits below the median, might benefit from recombinant erythropoietin therapy.
KeywordsPolycystic Kidney Disease Continuous Ambulatory Peritoneal Dialysis Folate Supplement Hematocrit Level Iron Therapy
Unable to display preview. Download preview PDF.
- 2.Editorial. The anemia of chronic renal failure. Lancet 1983; 1:965–966.Google Scholar
- 4.Saltissi D, Coles GA, Napier AF, Bentley P. The hematological response to continuous ambulatory peritoneal dialysis. Clin Neph 1984 Jul; 22(1):21–27.Google Scholar
- 5.Mehta BR, Mogridge C, Bell JD. Changes in red cell mass, plasma volume and hematocrit in patients of CAPD. Trans Am Soc Artif Organs 1983 Apr; 29:50–52.Google Scholar
- 7.Lampen S, Carozzi S, Icardi A. In vitro and in vivo studies of erythropoiesis during continuous ambulatory peritoneal dialysis. Peritoneal Dial Bull 1983 Apr–Jun; 3(2): 94–96.Google Scholar
- 11.Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythro-poietin: results of a phase I–II clinical trial. Am Soc Neph 1986 Dec 7–10; 19:41A. abstract.Google Scholar